About Actin, cytoplasmic 2
Actin, cytoplasmic 2 (ACTG1) is a protein
from Homo sapiens identified by UniProt accession
P63261, 375 residues long.
MolForge cross-references it against 0 known binders and
290 disease associations.
Target properties
| Protein name | Actin, cytoplasmic 2 |
|---|
| UniProt accession | P63261 |
|---|
| Gene | ACTG1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 375 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (290)
Diseases linked to this target (Open Targets).
- Baraitser-Winter syndrome · score 0.82
- autosomal dominant nonsyndromic hearing loss · score 0.65
- cancer · score 0.60
- Noonan syndrome · score 0.53
- hypertrophic cardiomyopathy · score 0.50
- Costello syndrome · score 0.50
- neurodegenerative disease · score 0.50
- genetic disorder · score 0.48
- nonsyndromic genetic hearing loss · score 0.45
- external ear disease · score 0.43
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P63261-F1 | alphafold | PREDICTED | 95.37 | — |
Amino-acid sequence (375 residues)
MEEEIAALVI DNGSGMCKAG FAGDDAPRAV FPSIVGRPRH QGVMVGMGQK DSYVGDEAQS KRGILTLKYP IEHGIVTNWD DMEKIWHHTF YNELRVAPEE HPVLLTEAPL NPKANREKMT QIMFETFNTP AMYVAIQAVL SLYASGRTTG IVMDSGDGVT HTVPIYEGYA LPHAILRLDL AGRDLTDYLM KILTERGYSF TTTAEREIVR DIKEKLCYVA LDFEQEMATA ASSSSLEKSY ELPDGQVITI GNERFRCPEA LFQPSFLGME SCGIHETTFN SIMKCDVDIR KDLYANTVLS GGTTMYPGIA DRMQKEITAL APSTMKIKII APPERKYSVW IGGSILASLS TFQQMWISKQ EYDESGPSIV HRKCF
Explore Actin, cytoplasmic 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets